Another "String to the Bow" of PJ34, a potent poly(ADP-Ribose)polymerase inhibitor: An antiplatelet effect through P2Y12 antagonism?

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Lechaftois, Marie ^a   Dreano, Elise ^a,b   Palmier, Bruno ^a   Margaill, Isabelle ^a   Marchand Leroux, Catherine ^a   Bachelot Loza, Christilla ^a,b   Lerouet, Dominique ^a  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^b Fondation Carpentier   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; DPQ; INO 1001; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN; ANTITHROMBOCYTIC AGENT; N-(OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)-N,N-DIMETHYLACETAMIDE HYDROCHLORIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; P2RY12 PROTEIN, HUMAN; PHENANTHRENE DERIVATIVE;

ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; STRUCTURE ANALYSIS; THROMBOCYTE AGGREGATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FEMALE; MALE; METABOLISM; SECRETION (PROCESS); STROKE; THROMBOCYTE;

ADENOSINE DIPHOSPHATE; BLOOD PLATELETS; FEMALE; HUMANS; MALE; PHENANTHRENES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; RECEPTORS, PURINERGIC P2Y12; STROKE;

EID: 84908181093     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110776     Document Type: Article

References (43)

1. del Zoppo GJ (1998) The role of platelets in ischemic stroke. Neurology 51 (3 Suppl 3): S9-14.
2. Yip HK, Liou CW, Chang HW, Lan MY, Liu JS, et al. (2005) Link between platelet activity and outcomes after an ischemic stroke. Cerebrovasc Dis 20: 120-128.
3. Stoll G, Kleinschnitz C, Nieswandt B (2008) Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood 112: 3555-3562.
4. Franks ZG, Campbell RA, Weyrich AS, Rondina MT (2010) Platelet-leukocyte interactions link inflammatory and thromboembolic events in ischemic stroke. Ann N Y Acad Sci 1207: 11-17.
5. Hacke W, Kaste M, Bluhmki E, Brozman M, ECASS Investigators, et al. (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359: 1317-1329.
6. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333: 1581-1587.
7. Rha JH, Saver JL (2007) The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 38: 967-973.
8. Alexandrov AV, Grotta JC (2002) Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 59: 862-867.
9. Rubiera M, Alvarez-Sabín J, Ribo M, Montaner J, Santamarina E, et al. (2005) Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke 36: 1452-1456.
10. Saqqur M, Molina CA, Salam A, Siddiqui M, CLOTBUST Investigators, et al. (2007) Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment: a multicenter transcranial Doppler study. Stroke 38: 69-74.
11. Balami JS, Sutherland BA, Buchan AM (2013) Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke. CNS Neurol Disord Drug Targets 12: 155-169.
12. Mohan KM, Wolfe CD, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, et al. (2011) Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke 42: 1489-1494.
13. Kirshner HS (2012) Antiplatelet and anticoagulation strategies in the prevention and treatment of ischemic stroke. Curr Pharm Des 18: 5261-5272.
14. Fabre JE, Gurney ME (2010) Limitations of current therapies to prevent thrombosis: a need for novel strategies. Mol Biosyst 6: 305-315.
15. Di Minno MN, Russolillo A, Camera M, Brambilla M, De Gregorio A, et al. (2011) New anti-thrombotic drugs for stroke prevention. Curr Vasc Pharmacol 9: 723-732.
16. Weber R, Brenck J, Diener HC (2012) Antiplatelet therapy in cerebrovascular disorders. Handb Exp Pharmacol 210: 519-546.
17. Alexy T, Toth A, Marton Z, Horvath B, Koltai K, et al. (2004) Inhibition of ADP-evoked platelet aggregation by selected poly(ADP-ribose) polymerase inhibitors. J Cardiovasc Pharmacol 43: 423-431.
18. Tóth O, Szabó C, Kecskés M, Pótó L, Nagy A, et al. (2006) In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters. Life Sci 79: 317-323.
19. Komjáti K, Besson VC, Szabó C (2005) Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma. Curr Drug Targets CNS Neurol Disord 4: 179-194.
20. Curtin NJ, Szabo C (2013) Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond. Mol Aspects Med 34: 1217-1256.
21. Abdelkarim GE, Gertz K, Harms C, Katchanov J, Dirnagl U, et al. (2001) Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int J Mol Med 7: 255-260.
22. Park EM, Cho S, Frys K, Racchumi G, Zhou P, et al. (2004) Interaction between inducible nitric oxide synthase and poly(ADP-ribose) polymerase in focal ischemic brain injury. Stroke 35: 2896-2901.
23. Haddad M, Rhinn H, Bloquel C, Coqueran B, Szabó C, et al. (2006) Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice. Br J Pharmacol 149: 23-30.
24. Haddad M, Beray-Berthat V, Coqueran B, Palmier B, Szabo C, et al. (2008) Reduction of hemorrhagic transformation by PJ34, a poly(ADP-ribose)polymerase inhibitor, after permanent focal cerebral ischemia in mice. Eur J Pharmacol 588: 52-57.
25. Haddad M, Beray-Berthat V, Coqueran B, Plotkine M, Marchand-Leroux C, et al. (2013) Combined therapy with PJ34, a poly(ADP-ribose)polymerase inhibitor, reduces tissue plasminogen activator-induced hemorrhagic transformations in cerebral ischemia in mice. Fundam Clin Pharmacol 27: 393-401.
26. Lenzsér G, Kis B, Snipes JA, Gáspár T, Sándor P, et al. (2007) Contribution of poly(ADP-ribose) polymerase to postischemic blood-brain barrier damage in rats. J Cereb Blood Flow Metab 27: 1318-1326.
27. Kauppinen TM, Suh SW, Berman AE, Hamby AM, Swanson RA (2009) Inhibition of poly(ADP-ribose) polymerase suppresses inflammation and promotes recovery after ischemic injury. J Cereb Blood Flow Metab 29: 820-829.
28. Teng F, Beray-Berthat V, Coqueran B, Lesbats C, Kuntz M, et al. (2013) Prevention of rt-PA induced blood-brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice. Exp Neurol 248: 416-428.
29. Takahashi K, Pieper AA, Croul SE, Zhang J, Snyder SH, et al. (1999) Post-treatment with an inhibitor of poly(ADP-ribose) polymerase attenuates cerebral damage in focal ischemia. Brain Res 829: 46-54.
30. Giovannelli L, Cozzi A, Guarnieri I, Dolara P, Moroni F (2002) Comet assay as a novel approach for studying DNA damage in focal cerebral ischemia: differential effects of NMDA receptor antagonists and poly(ADP-ribose) polymerase inhibitors. J Cereb Blood Flow Metab 22: 697-704.
31. Komjáti K, Mabley JG, Virág L, Southan GJ, Salzman AL, et al. (2004) Poly(ADP-ribose) polymerase inhibition protect neurons and the white matter and regulates the translocation of apoptosis-inducing factor in stroke. Int J Mol Med 13: 373-382.
32. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, et al. (2005) Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 3: 85-92.
33. Xiang B, Zhang G, Ren H, Sunkara M, Morris AJ, et al. (2012) The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism. PLoS One 7: e51037.
34. Broos K, Feys HB, De Meyer SF, Vanhoorelbeke K, Deckmyn H (2011) Platelets at work in primary hemostasis. Blood Rev 25: 155-167.
35. Varga-Szabo D, Braun A, Nieswandt B (2009) Calcium signaling in platelets. J Thromb Haemost 7: 1057-1066.
36. 12 receptor in platelet activation. J Clin Invest 113: 340-345.
37. Gachet C (2008) P2 receptors, platelet function and pharmacological implications. Thromb Haemost 99: 466-472.
38. 12 antagonist. Arterioscler Thromb Vasc Biol 31: 416-422.
39. Szepes M, Janicsek Z, Benko Z, Cselenyák A, Kiss L (2013) Pretreatment of therapeutic cells with poly(ADP-ribose) polymerase inhibitor enhances their efficacy in an in vitro model of cell-based therapy in myocardial infarct. Int J Mol Med 31: 26-32.
40. Mathews MT, Berk BC (2008) PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2. Arterioscler Thromb Vasc Biol 28: 711-717.
41. Madison DL, Stauffer D, Lundblad JR (2011) The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest. DNA Repair (Amst) 10: 1003-1013.
42. Antolín AA, Jalencas X, Yélamos J, Mestres J (2012) Identification of pim kinases as novel targets for PJ34 with confounding effects in PARP biology. ACS Chem Biol 7: 1962-1967.
43. Nasrabady SE, Kuzhandaivel A, Akrami A, Bianchetti E, Milanese M, et al. (2012) Unusual increase in lumbar network excitability of the rat spinal cord evoked by the PARP-1 inhibitor PJ-34 through inhibition of glutamate uptake. Neuropharmacology 63: 415-426.